



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/782,015	02/12/2001	Edmund Y.M. Chein	00115P002D	2156
8791	7590 08/22/2005		EXAMINER	
BLAKELY SOKOLOFF TAYLOR & ZAFMAN			GUPTA, ANISH	
SEVENTH I	SHIRE BOULEVARD FLOOR		ART UNIT	PAPER NUMBER
LOS ANGELES, C	LES, CA 90025-1030		1654	
	•	·	DATE MAILED: 08/22/2003	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/782,015	CHEIN, EDMUND Y.M.				
Office Action Summary	Examiner	Art Unit				
•	Anish Gupta	1654				
The MAILING DATE of this communic	,	ith the correspondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FO THE MAILING DATE OF THIS COMMUNIC - Extensions of time may be available under the provisions or after SIX (6) MONTHS from the mailing date of this commu - If the period for reply specified above is less than thirty (30) - If NO period for reply is specified above, the maximum state - Failure to reply within the set or extended period for reply w Any reply received by the Office later than three months aft earned patent term adjustment. See 37 CFR 1.704(b).	CATION. f 37 CFR 1.136(a). In no event, however, may a inication. d days, a reply within the statutory minimum of thi utory period will apply and will expire SIX (6) MOI vill, by statute, cause the application to become A	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed	I on <u>13 June 2005</u> .	,				
<u> </u>						
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practic	e under <i>Ex part</i> e Quayle, 1935 C.E). 11, 453 O.G. 213.				
Disposition of Claims						
4) ☐ Claim(s) 10-20 is/are pending in the a 4a) Of the above claim(s) is/are 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 10-20 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction	e withdrawn from consideration.					
Application Papers						
9) The specification is objected to by the	Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any object						
Replacement drawing sheet(s) including t 11) The oath or declaration is objected to	•					
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for a) All b) Some * c) None of: 1. Certified copies of the priority of Some * c) 2. Certified copies of the priority of Some * c) 3. Copies of the certified copies of application from the Internation * See the attached detailed Office action	documents have been received. documents have been received in A f the priority documents have beer nal Bureau (PCT Rule 17.2(a)).	Application No received in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	· 4) Interview	Summary (PTO-413)				
Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO-1449 or Paper No(s)/Mail Date	O-948) Paper No(s)/Mail Date nformal Patent Application (PTO-152)				

Application/Control Number: 09/782,015

Art Unit: 1654

DETAILED ACTION

1. The amendment filed, 6-13-05, is acknowledged. Claims 10, 14and 18 were amended by the amendment. Claims 10-20 are pending in this application.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 10-20 remain rejected under 35 U.S.C. 102(b) as being anticipated by Chein (GB2320190).

The claims are drawn to kit with human growth hormone and a supplemental hormone that is administered separately.

Applicants argue that the Chein deals with administering hormones as anti-aging treatments. Multiple sclerosis is not a disease associated with degenerative conditions that occur as a result of old age. Accordingly, there is no motivation in Chein to provide a regimen for administration of various hormones for reducing symptoms commonly associated with multiple sclerosis.

Applicants arguments, filed 6-13-05, have been considered but have not been found persuasive.

First, the rejection, in the previous office action was based upon anticipation under 102 and not obviousness under 103. Statements regarding motivation are not necessary for this rejection.

Secondly, as stated in the previous office action, the reference discloses all of the components to

Application/Control Number: 09/782,015

Art Unit: 1654

that kit. Applicants have not presented any difference between the disclosed components of the kit and the instant components. Where the claimed and prior art products are identical or substantially identical in structure or composition, a prima facie case of either anticipation or obviousness has been established. In re Best, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." In re Spada, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. In re Best, supra. It does not matter what the intended use of the kit is in this application or the prior art, so long as the products are identical. Here, the products are identical including the dosage regiment, as pointed out in the office action dated 5-27-04, and thus the claims are anticipated.

3. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 09/782,015

Art Unit: 1654

4. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Anish Gupta whose telephone number is (571)272-0965. If attempts to reach

Page 4

the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, can normally

be reached on (571) 272-0974. The fax phone number of this group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application should be directed

to the Group receptionist whose telephone number is (703) 308-0196.

Patent Examiner